| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Burning Rock Biotech Limited (NASDAQ: BNR)
BNR Technical Analysis
5
| As on 9th Jun 2023 BNR STOCK Price closed @ 2.20 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.16 & Strong Sell for SHORT-TERM with Stoploss of 8.99 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BNRSTOCK Price
| Open | 2.28 | Change | Price | % |
| High | 2.28 | 1 Day | -0.03 | -1.35 |
| Low | 2.15 | 1 Week | -0.46 | -17.29 |
| Close | 2.20 | 1 Month | -0.64 | -22.54 |
| Volume | 18900 | 1 Year | -8.30 | -79.05 |
| 52 Week High 10.74 | 52 Week Low 1.73 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BNR Daily Charts |
BNR Intraday Charts |
Whats New @ Bazaartrend |
BNR Free Analysis |
|
|
BNR Important Levels Intraday
| RESISTANCE | 2.45 |
| RESISTANCE | 2.37 |
| RESISTANCE | 2.32 |
| RESISTANCE | 2.27 |
| SUPPORT | 2.13 |
| SUPPORT | 2.08 |
| SUPPORT | 2.03 |
| SUPPORT | 1.95 |
BNR Forecast May 2024
| 4th UP Forecast | 7 |
| 3rd UP Forecast | 5.46 |
| 2nd UP Forecast | 4.51 |
| 1st UP Forecast | 3.56 |
| 1st DOWN Forecast | 0.84 |
| 2nd DOWN Forecast | -0.11 |
| 3rd DOWN Forecast | -1.06 |
| 4th DOWN Forecast | -2.6 |
BNR Weekly Forecast
| 4th UP Forecast | 5.73 |
| 3rd UP Forecast | 4.60 |
| 2nd UP Forecast | 3.90 |
| 1st UP Forecast | 3.20 |
| 1st DOWN Forecast | 1.20 |
| 2nd DOWN Forecast | 0.50 |
| 3rd DOWN Forecast | -0.20 |
| 4th DOWN Forecast | -1.33 |
BNR Forecast2024
| 4th UP Forecast | 20.64 |
| 3rd UP Forecast | 14.73 |
| 2nd UP Forecast | 11.07 |
| 1st UP Forecast | 7.42 |
| 1st DOWN Forecast | -3.02 |
| 2nd DOWN Forecast | -6.67 |
| 3rd DOWN Forecast | -10.33 |
| 4th DOWN Forecast | -16.24 |
Burning Rock Biotech Limited ( NASDAQ USA Symbol : BNR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BNR Business Profile
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China. Address: Building 3, Standard Industrial Unit 2, Guangzhou, China, 510005
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service